{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:41:07Z","timestamp":1791168067536,"version":"4.1.0"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ag processing by intracellular proteases and peptidases and epitope presentation are critical for recognition of pathogen-infected cells by CD8+ T lymphocytes. First-generation HIV protease inhibitors (PIs) alter proteasome activity, but the effect of first- or second-generation PIs on other cellular peptidases, the underlying mechanism, and impact on Ag processing and epitope presentation to CTL are still unknown. In this article, we demonstrate that several HIV PIs altered not only proteasome but also aminopeptidase activities in PBMCs. Using an in vitro degradation assay involving PBMC cytosolic extracts, we showed that PIs altered the degradation patterns of oligopeptides and peptide production in a sequence-specific manner, enhancing the cleavage of certain residues and reducing others. PIs affected the sensitivity of peptides to intracellular degradation, and altered the kinetics and amount of HIV epitopes produced intracellularly. Accordingly, the endogenous degradation of incoming virions in the presence of PIs led to variations in CTL-mediated killing of HIV-infected cells. By altering host protease activities and the degradation patterns of proteins in a sequence-specific manner, HIV PIs may diversify peptides available for MHC class I presentation to CTL, alter the patterns of CTL responses, and provide a complementary approach to current therapies for the CTL-mediated clearance of abnormal cells in infection, cancer, or other immune disease.<\/jats:p>","DOI":"10.4049\/jimmunol.1302805","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T03:15:24Z","timestamp":1394507724000},"page":"3496-3506","source":"Crossref","is-referenced-by-count":18,"title":["Sequence-Specific Alterations of Epitope Production by HIV Protease Inhibitors"],"prefix":"10.1093","volume":"192","author":[{"given":"Georgio","family":"Kourjian","sequence":"first","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School , Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School , Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijah","family":"Mondesire-Crump","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School , Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Shimada","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School , Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Gourdain","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School , Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Le Gall","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School , Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,4,15]]},"reference":[{"key":"2025032404251174200_r1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"key":"2025032404251174200_r2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"2025032404251174200_r3","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1517\/14656560902980202","article-title":"HIV protease inhibitors: recent clinical trials and recommendations on use","volume":"10","author":"Fern\u00e1ndez-Montero","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"2025032404251174200_r4","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"2025032404251174200_r5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0025-7753(04)74368-7","article-title":"[Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients]","volume":"122","author":"Ena","year":"2004","journal-title":"Med. Clin. (Barc.)"},{"key":"2025032404251174200_r6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00126334-199907010-00005","article-title":"Insulin resistance in HIV protease inhibitor-associated diabetes","volume":"21","author":"Yarasheski","year":"1999","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"2025032404251174200_r7","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"AIDS"},{"key":"2025032404251174200_r8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/COH.0b013e328312c392","article-title":"Toxicity of HIV protease inhibitors: clinical considerations","volume":"3","author":"Boesecke","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2025032404251174200_r9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","article-title":"Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial","volume":"14","author":"Orkin","year":"2013","journal-title":"HIV Med."},{"key":"2025032404251174200_r10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.2200122","article-title":"Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease","volume":"249","author":"Erickson","year":"1990","journal-title":"Science"},{"key":"2025032404251174200_r11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1186\/1471-2105-11-479","article-title":"Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome","volume":"11","author":"Diez-Rivero","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"2025032404251174200_r12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nature02263","article-title":"Protein degradation and protection against misfolded or damaged proteins","volume":"426","author":"Goldberg","year":"2003","journal-title":"Nature"},{"key":"2025032404251174200_r13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1074-7613(03)00058-X","article-title":"The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation","volume":"18","author":"York","year":"2003","journal-title":"Immunity"},{"key":"2025032404251174200_r14","doi-asserted-by":"crossref","first-page":"46723","DOI":"10.1074\/jbc.M406537200","article-title":"Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases","volume":"279","author":"Saric","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2025032404251174200_r15","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.4049\/jimmunol.0803564","article-title":"Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivo","volume":"183","author":"Kawahara","year":"2009","journal-title":"J. Immunol."},{"key":"2025032404251174200_r16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature01074","article-title":"ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum","volume":"419","author":"Serwold","year":"2002","journal-title":"Nature"},{"key":"2025032404251174200_r17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/ni860","article-title":"The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues","volume":"3","author":"York","year":"2002","journal-title":"Nat. Immunol."},{"key":"2025032404251174200_r18","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1172\/JCI44932","article-title":"Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape","volume":"121","author":"Lazaro","year":"2011","journal-title":"J. Clin. Invest."},{"key":"2025032404251174200_r19","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.176.5.2697","article-title":"Cutting edge: HLA-B27 acquires many N-terminal dibasic peptides: coupling cytosolic peptide stability to antigen presentation","volume":"176","author":"Herberts","year":"2006","journal-title":"J. Immunol."},{"key":"2025032404251174200_r20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1074-7613(02)00511-3","article-title":"Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I","volume":"18","author":"Reits","year":"2003","journal-title":"Immunity"},{"key":"2025032404251174200_r21","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1074\/jbc.274.6.3363","article-title":"The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation","volume":"274","author":"Kisselev","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2025032404251174200_r22","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.4049\/jimmunol.0803663","article-title":"The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum","volume":"183","author":"Hearn","year":"2009","journal-title":"J. Immunol."},{"key":"2025032404251174200_r23","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.4049\/jimmunol.180.5.3210","article-title":"Characterizing the N-terminal processing motif of MHC class I ligands","volume":"180","author":"Schatz","year":"2008","journal-title":"J. Immunol."},{"key":"2025032404251174200_r24","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.4049\/jimmunol.1200219","article-title":"Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals","volume":"188","author":"Zhang","year":"2012","journal-title":"J. Immunol."},{"key":"2025032404251174200_r25","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1172\/JCI32047","article-title":"Portable flanking sequences modulate CTL epitope processing","volume":"117","author":"Le Gall","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2025032404251174200_r26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/599837","article-title":"Differential HIV epitope processing in monocytes and CD4 T cells affects cytotoxic T lymphocyte recognition","volume":"200","author":"Lazaro","year":"2009","journal-title":"J. Infect. Dis."},{"key":"2025032404251174200_r27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0092-8674(94)90462-6","article-title":"Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules","volume":"78","author":"Rock","year":"1994","journal-title":"Cell"},{"key":"2025032404251174200_r28","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.0603095103","article-title":"Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance","volume":"103","author":"York","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032404251174200_r29","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.4049\/jimmunol.0903712","article-title":"Endoplasmic reticulum aminopeptidase associated with antigen processing defines the composition and structure of MHC class I peptide repertoire in normal and virus-infected cells","volume":"184","author":"Blanchard","year":"2010","journal-title":"J. Immunol."},{"key":"2025032404251174200_r30","doi-asserted-by":"crossref","first-page":"13120","DOI":"10.1073\/pnas.95.22.13120","article-title":"An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses","volume":"95","author":"Andr\u00e9","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032404251174200_r31","first-page":"6901","article-title":"Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis","volume":"62","author":"Gaedicke","year":"2002","journal-title":"Cancer Res."},{"key":"2025032404251174200_r32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1089\/088922201300343744","article-title":"Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes","volume":"17","author":"Kelleher","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"2025032404251174200_r33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/135965350501000203","article-title":"The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function","volume":"10","author":"Piccinini","year":"2005","journal-title":"Antivir. Ther. (Lond.)"},{"key":"2025032404251174200_r34","first-page":"5230","article-title":"The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells","volume":"62","author":"Pajonk","year":"2002","journal-title":"Cancer Res."},{"key":"2025032404251174200_r35","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1093\/infdis\/jit112","article-title":"Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy\u2014implications for sustained efficacy of ART in resource-limited settings","volume":"207","author":"Hill","year":"2013","journal-title":"J. Infect. Dis."},{"key":"2025032404251174200_r36","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/jit107","article-title":"Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings","volume":"207","author":"Hosseinipour","year":"2013","journal-title":"J. Infect. Dis."},{"key":"2025032404251174200_r37","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0076-6879(05)98030-0","article-title":"Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates","volume":"398","author":"Kisselev","year":"2005","journal-title":"Methods Enzymol."},{"key":"2025032404251174200_r38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jim.2013.09.009","article-title":"A real-time killing assay to follow viral epitope presentation to CD8 T cells","volume":"398\u2013399","author":"Gourdain","year":"2013","journal-title":"J. Immunol. Methods"},{"key":"2025032404251174200_r39","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1086\/313852","article-title":"Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors","volume":"30","author":"Acosta","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"2025032404251174200_r40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00126334-200304010-00005","article-title":"Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects","volume":"32","author":"Cardiello","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"2025032404251174200_r41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350400900103","article-title":"Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients","volume":"9","author":"Hennessy","year":"2004","journal-title":"Antivir. Ther. (Lond.)"},{"key":"2025032404251174200_r42","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/QAI.0b013e3182364c67","article-title":"Plasma and intracellular pharmacokinetics of darunavir\/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals","volume":"58","author":"Jackson","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"2025032404251174200_r43","doi-asserted-by":"crossref","first-page":"F103","DOI":"10.1097\/00002030-200006160-00003","article-title":"Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study","volume":"14","author":"van Heeswijk","year":"2000","journal-title":"AIDS"},{"key":"2025032404251174200_r44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1074-7613(04)00074-3","article-title":"A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation","volume":"20","author":"Reits","year":"2004","journal-title":"Immunity"},{"key":"2025032404251174200_r45","first-page":"1","volume-title":"HIV Molecular Immunology 2008.","author":"Frahm","year":"2008"},{"key":"2025032404251174200_r46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ab.2004.02.007","article-title":"Use of cellular glucose-6-phosphate dehydrogenase for cell quantitation: applications in cytotoxicity and apoptosis assays","volume":"329","author":"Batchelor","year":"2004","journal-title":"Anal. Biochem."},{"key":"2025032404251174200_r47","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1367-5931(03)00084-X","article-title":"Prolyl peptidases: a serine protease subfamily with high potential for drug discovery","volume":"7","author":"Rosenblum","year":"2003","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2025032404251174200_r48","doi-asserted-by":"crossref","first-page":"35734","DOI":"10.1074\/jbc.274.50.35734","article-title":"How an inhibitor of the HIV-I protease modulates proteasome activity","volume":"274","author":"Schmidtke","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2025032404251174200_r49","doi-asserted-by":"crossref","first-page":"966.e13","DOI":"10.1016\/j.urology.2011.11.033","article-title":"Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells","volume":"79","author":"Sato","year":"2012","journal-title":"Urology"},{"key":"2025032404251174200_r50","doi-asserted-by":"crossref","first-page":"E3454","DOI":"10.1073\/pnas.1213640109","article-title":"Proteasome allostery as a population shift between interchanging conformers","volume":"109","author":"Ruschak","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032404251174200_r51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/bip.21381","article-title":"Potential allosteric modulators of the proteasome activity","volume":"93","author":"Jankowska","year":"2010","journal-title":"Biopolymers"},{"key":"2025032404251174200_r52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)80341-X","article-title":"Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown","volume":"4","author":"Kisselev","year":"1999","journal-title":"Mol. Cell"},{"key":"2025032404251174200_r53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/01.ATV.0000198749.28422.29","article-title":"HIV protease inhibitors and hyperlipidemia: a fatty acid connection","volume":"26","author":"Spector","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2025032404251174200_r54","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MED.0b013e32833dde87","article-title":"HIV protease inhibitors and obesity","volume":"17","author":"Anuurad","year":"2010","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"2025032404251174200_r55","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","volume":"20","author":"Noor","year":"2006","journal-title":"AIDS"},{"key":"2025032404251174200_r56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00204-010-0527-7","article-title":"Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia","volume":"84","author":"Waring","year":"2010","journal-title":"Arch. Toxicol."},{"key":"2025032404251174200_r57","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygeno.2007.06.004","article-title":"Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia","volume":"90","author":"Lum","year":"2007","journal-title":"Genomics"},{"key":"2025032404251174200_r58","doi-asserted-by":"crossref","first-page":"21517","DOI":"10.1074\/jbc.M301032200","article-title":"Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes","volume":"278","author":"Meiners","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2025032404251174200_r59","doi-asserted-by":"crossref","first-page":"37514","DOI":"10.1074\/jbc.M104557200","article-title":"HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus","volume":"276","author":"Riddle","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2025032404251174200_r60","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1074\/jbc.M406309200","article-title":"Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane","volume":"280","author":"Kramer","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2025032404251174200_r61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MOL.0b013e32813fa2e2","article-title":"Intestinal cholesterol transport proteins: an update and beyond","volume":"18","author":"Levy","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"key":"2025032404251174200_r62","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1042\/BJ20060793","article-title":"Insulin-stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase","volume":"402","author":"Yeh","year":"2007","journal-title":"Biochem. J."},{"key":"2025032404251174200_r63","doi-asserted-by":"crossref","first-page":"17907","DOI":"10.1074\/jbc.272.29.17907","article-title":"A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis","volume":"272","author":"Thornberry","year":"1997","journal-title":"J. Biol. Chem."},{"key":"2025032404251174200_r64","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.4049\/jimmunol.174.12.7524","article-title":"HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response","volume":"174","author":"Feeney","year":"2005","journal-title":"J. Immunol."},{"key":"2025032404251174200_r65","doi-asserted-by":"crossref","first-page":"12952","DOI":"10.1128\/JVI.79.20.12952-12960.2005","article-title":"De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection","volume":"79","author":"Allen","year":"2005","journal-title":"J. Virol."},{"key":"2025032404251174200_r66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-8-63","article-title":"Viral suppression of multiple escape mutants by de novo CD8(+) T cell responses in a human immunodeficiency virus-1 infected elite suppressor","volume":"8","author":"O\u2019Connell","year":"2011","journal-title":"Retrovirology"},{"key":"2025032404251174200_r67","doi-asserted-by":"crossref","first-page":"7131","DOI":"10.4049\/jimmunol.0803658","article-title":"Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection","volume":"182","author":"Turnbull","year":"2009","journal-title":"J. Immunol."},{"key":"2025032404251174200_r68","first-page":"380","article-title":"Vertical T cell immunodominance and epitope entropy determine HIV-1 escape","volume":"123","author":"Liu","year":"2013","journal-title":"J. Clin. Invest."},{"key":"2025032404251174200_r69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm0297-205","article-title":"Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus","volume":"3","author":"Borrow","year":"1997","journal-title":"Nat. Med."},{"key":"2025032404251174200_r70","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/375606a0","article-title":"Antigenic oscillations and shifting immunodominance in HIV-1 infections","volume":"375","author":"Nowak","year":"1995","journal-title":"Nature"},{"key":"2025032404251174200_r71","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"2025032404251174200_r72","first-page":"318","article-title":"HIV-1 eradication strategies: design and assessment","volume":"8","author":"Siliciano","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2025032404251174200_r73","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11904-012-0111-2","article-title":"Antiviral drugs and the treatment of hepatitis C","volume":"9","author":"Jalali","year":"2012","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"2025032404251174200_r74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/QCO.0b013e32835ba8f9","article-title":"When to start antiretroviral therapy during tuberculosis treatment?","volume":"26","author":"Naidoo","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"2025032404251174200_r75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/fvl.12.123","article-title":"HIV-1 and the immune response to TB","volume":"8","author":"Walker","year":"2013","journal-title":"Future Virol."},{"key":"2025032404251174200_r76","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2011.049981","article-title":"The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo","volume":"97","author":"Bono","year":"2012","journal-title":"Haematologica"},{"key":"2025032404251174200_r77","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1038\/cddis.2012.87","article-title":"Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells","volume":"3","author":"Kawabata","year":"2012","journal-title":"Cell Death Dis."},{"key":"2025032404251174200_r78","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1158\/1535-7163.MCT-07-2375","article-title":"Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis","volume":"7","author":"Kraus","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"2025032404251174200_r79","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(03)01192-6","article-title":"Use of HIV protease inhibitors to block Kaposi\u2019s sarcoma and tumour growth","volume":"4","author":"Sgadari","year":"2003","journal-title":"Lancet Oncol."},{"key":"2025032404251174200_r80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4161\/cbt.12.7.17172","article-title":"Nelfinavir induces radiation sensitization in pituitary adenoma cells","volume":"12","author":"Zeng","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"2025032404251174200_r81","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-09-1324","article-title":"Radiosensitization of epidermal growth factor receptor\/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status","volume":"16","author":"Kimple","year":"2010","journal-title":"Clin. Cancer Res."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/192\/8\/3496\/61760333\/1302805.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/192\/8\/3496\/61760333\/1302805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T08:52:07Z","timestamp":1742806327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/192\/8\/3496\/8001592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,4,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1302805","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,4]]},"published":{"date-parts":[[2014,4]]}}}